25 XP   0   0   10

Sartorius Stedim Biotech SA
Buy, Hold or Sell?

Let's analyse Sartorius together

PenkeI guess you are interested in Sartorius Stedim Biotech SA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Sartorius Stedim Biotech SA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Sartorius Stedim Biotech SA

I send you an email if I find something interesting about Sartorius Stedim Biotech SA.

Quick analysis of Sartorius (30 sec.)










What can you expect buying and holding a share of Sartorius? (30 sec.)

How much money do you get?

How much money do you get?
€1.45
When do you have the money?
1 year
How often do you get paid?
79.3%

What is your share worth?

Current worth
€27.47
Expected worth in 1 year
€29.10
How sure are you?
96.6%

+ What do you gain per year?

Total Gains per Share
€3.00
Return On Investment
1.5%

For what price can you sell your share?

Current Price per Share
€200.60
Expected price per share
€165.56 - €248.30
How sure are you?
50%

1. Valuation of Sartorius (5 min.)




Live pricePrice per Share (EOD)

€200.60

Intrinsic Value Per Share

€85.57 - €101.53

Total Value Per Share

€113.04 - €129.00

2. Growth of Sartorius (5 min.)




Is Sartorius growing?

Current yearPrevious yearGrowGrow %
How rich?$2.8b$2.3b$364.1m13.2%

How much money is Sartorius making?

Current yearPrevious yearGrowGrow %
Making money$82.4m$233.1m-$150.7m-182.9%
Net Profit Margin11.1%25.1%--

How much money comes from the company's main activities?

3. Financial Health of Sartorius (5 min.)




4. Comparing to competitors in the Medical Instruments & Supplies industry (5 min.)




  Industry Rankings (Medical Instruments & Supplies)  


Richest
#20 / 171

Most Revenue
#38 / 171

Most Profit
#30 / 171

What can you expect buying and holding a share of Sartorius? (5 min.)

Welcome investor! Sartorius's management wants to use your money to grow the business. In return you get a share of Sartorius.

What can you expect buying and holding a share of Sartorius?

First you should know what it really means to hold a share of Sartorius. And how you can make/lose money.

Speculation

The Price per Share of Sartorius is €200.60. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Sartorius.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sartorius, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €27.47. Based on the TTM, the Book Value Change Per Share is €0.41 per quarter. Based on the YOY, the Book Value Change Per Share is €2.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.34 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Sartorius.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.440.2%0.550.3%2.401.2%1.140.6%0.940.5%
Usd Book Value Change Per Share0.490.2%0.430.2%2.141.1%0.890.4%1.010.5%
Usd Dividend Per Share0.000.0%0.360.2%1.000.5%0.480.2%0.390.2%
Usd Total Gains Per Share0.490.2%0.800.4%3.131.6%1.370.7%1.400.7%
Usd Price Per Share254.97-259.82-343.71-293.05-227.02-
Price to Earnings Ratio146.40-159.64-36.15-146.32-113.70-
Price-to-Total Gains Ratio523.74-474.03-113.04-822.68-608.32-
Price to Book Ratio8.72-9.20-14.17-15.44-13.20-
Price-to-Total Gains Ratio523.74-474.03-113.04-822.68-608.32-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share213.55876
Number of shares4
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.360.48
Usd Book Value Change Per Share0.430.89
Usd Total Gains Per Share0.801.37
Gains per Quarter (4 shares)3.195.48
Gains per Year (4 shares)12.7621.91
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
167381412
2121416152934
3172129234356
4232842315778
52935553871100
63542684686122
741498154100144
846569461114166
9526310769128188
10587012077143210

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%29.00.00.0100.0%29.00.00.0100.0%
Book Value Change Per Share3.01.00.075.0%10.02.00.083.3%18.02.00.090.0%26.03.00.089.7%26.03.00.089.7%
Dividend per Share1.00.03.025.0%7.00.05.058.3%14.00.06.070.0%23.00.06.079.3%23.00.06.079.3%
Total Gains per Share4.00.00.0100.0%11.01.00.091.7%19.01.00.095.0%28.01.00.096.6%28.01.00.096.6%

Fundamentals of Sartorius

About Sartorius Stedim Biotech SA

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.

Fundamental data was last updated by Penke on 2024-04-09 13:56:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Sartorius Stedim Biotech SA.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Sartorius earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Sartorius to the Medical Instruments & Supplies industry mean.
  • A Net Profit Margin of 5.6% means that €0.06 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sartorius Stedim Biotech SA:

  • The MRQ is 5.6%. The company is making a profit. +1
  • The TTM is 11.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ5.6%TTM11.1%-5.5%
TTM11.1%YOY25.1%-14.0%
TTM11.1%5Y17.2%-6.0%
5Y17.2%10Y16.7%+0.5%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ5.6%6.3%-0.7%
TTM11.1%6.5%+4.6%
YOY25.1%8.2%+16.9%
5Y17.2%7.3%+9.9%
10Y16.7%7.6%+9.1%
1.1.2. Return on Assets

Shows how efficient Sartorius is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Sartorius to the Medical Instruments & Supplies industry mean.
  • 0.5% Return on Assets means that Sartorius generated €0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sartorius Stedim Biotech SA:

  • The MRQ is 0.5%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 1.4%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.5%TTM1.4%-0.9%
TTM1.4%YOY4.8%-3.4%
TTM1.4%5Y3.2%-1.8%
5Y3.2%10Y3.2%+0.0%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5%1.3%-0.8%
TTM1.4%1.4%0.0%
YOY4.8%2.0%+2.8%
5Y3.2%2.1%+1.1%
10Y3.2%2.0%+1.2%
1.1.3. Return on Equity

Shows how efficient Sartorius is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Sartorius to the Medical Instruments & Supplies industry mean.
  • 1.5% Return on Equity means Sartorius generated €0.02 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sartorius Stedim Biotech SA:

  • The MRQ is 1.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.5%TTM3.1%-1.6%
TTM3.1%YOY10.3%-7.2%
TTM3.1%5Y6.3%-3.3%
5Y6.3%10Y5.9%+0.4%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5%2.6%-1.1%
TTM3.1%2.9%+0.2%
YOY10.3%3.9%+6.4%
5Y6.3%3.8%+2.5%
10Y5.9%3.9%+2.0%

1.2. Operating Efficiency of Sartorius Stedim Biotech SA.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Sartorius is operating .

  • Measures how much profit Sartorius makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Sartorius to the Medical Instruments & Supplies industry mean.
  • An Operating Margin of 6.5% means the company generated €0.06  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sartorius Stedim Biotech SA:

  • The MRQ is 6.5%. The company is operating less efficient.
  • The TTM is 17.2%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ6.5%TTM17.2%-10.7%
TTM17.2%YOY33.0%-15.8%
TTM17.2%5Y24.5%-7.3%
5Y24.5%10Y24.1%+0.4%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ6.5%7.9%-1.4%
TTM17.2%7.5%+9.7%
YOY33.0%11.4%+21.6%
5Y24.5%10.2%+14.3%
10Y24.1%10.7%+13.4%
1.2.2. Operating Ratio

Measures how efficient Sartorius is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • An Operation Ratio of 0.94 means that the operating costs are €0.94 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Sartorius Stedim Biotech SA:

  • The MRQ is 0.935. The company is less efficient in keeping operating costs low.
  • The TTM is 0.860. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.935TTM0.860+0.075
TTM0.860YOY0.690+0.170
TTM0.8605Y0.796+0.064
5Y0.79610Y0.870-0.074
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9351.133-0.198
TTM0.8601.124-0.264
YOY0.6901.105-0.415
5Y0.7961.097-0.301
10Y0.8701.056-0.186

1.3. Liquidity of Sartorius Stedim Biotech SA.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Sartorius is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A Current Ratio of 1.51 means the company has €1.51 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Sartorius Stedim Biotech SA:

  • The MRQ is 1.510. The company is able to pay all its short-term debts. +1
  • The TTM is 1.620. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.510TTM1.620-0.110
TTM1.620YOY1.524+0.096
TTM1.6205Y1.549+0.071
5Y1.54910Y1.503+0.046
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5102.320-0.810
TTM1.6202.382-0.762
YOY1.5242.575-1.051
5Y1.5492.627-1.078
10Y1.5032.623-1.120
1.3.2. Quick Ratio

Measures if Sartorius is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Sartorius to the Medical Instruments & Supplies industry mean.
  • A Quick Ratio of 0.48 means the company can pay off €0.48 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sartorius Stedim Biotech SA:

  • The MRQ is 0.480. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.506. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.480TTM0.506-0.026
TTM0.506YOY0.569-0.063
TTM0.5065Y0.609-0.102
5Y0.60910Y0.630-0.021
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4801.111-0.631
TTM0.5061.159-0.653
YOY0.5691.286-0.717
5Y0.6091.423-0.814
10Y0.6301.521-0.891

1.4. Solvency of Sartorius Stedim Biotech SA.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Sartorius assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Sartorius to Medical Instruments & Supplies industry mean.
  • A Debt to Asset Ratio of 0.66 means that Sartorius assets are financed with 65.5% credit (debt) and the remaining percentage (100% - 65.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Sartorius Stedim Biotech SA:

  • The MRQ is 0.655. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.585. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.655TTM0.585+0.070
TTM0.585YOY0.519+0.066
TTM0.5855Y0.484+0.101
5Y0.48410Y0.450+0.034
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6550.351+0.304
TTM0.5850.357+0.228
YOY0.5190.357+0.162
5Y0.4840.359+0.125
10Y0.4500.371+0.079
1.4.2. Debt to Equity Ratio

Measures if Sartorius is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Sartorius to the Medical Instruments & Supplies industry mean.
  • A Debt to Equity ratio of 192.5% means that company has €1.93 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sartorius Stedim Biotech SA:

  • The MRQ is 1.925. The company is just able to pay all its debts with equity.
  • The TTM is 1.519. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.925TTM1.519+0.406
TTM1.519YOY1.117+0.402
TTM1.5195Y1.035+0.484
5Y1.03510Y0.903+0.133
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9250.541+1.384
TTM1.5190.559+0.960
YOY1.1170.545+0.572
5Y1.0350.610+0.425
10Y0.9030.669+0.234

2. Market Valuation of Sartorius Stedim Biotech SA

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Sartorius generates.

  • Above 15 is considered overpriced but always compare Sartorius to the Medical Instruments & Supplies industry mean.
  • A PE ratio of 146.40 means the investor is paying €146.40 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sartorius Stedim Biotech SA:

  • The EOD is 122.619. Based on the earnings, the company is expensive. -2
  • The MRQ is 146.398. Based on the earnings, the company is expensive. -2
  • The TTM is 159.645. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD122.619MRQ146.398-23.778
MRQ146.398TTM159.645-13.247
TTM159.645YOY36.148+123.497
TTM159.6455Y146.319+13.326
5Y146.31910Y113.698+32.621
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD122.61915.252+107.367
MRQ146.39817.745+128.653
TTM159.64518.883+140.762
YOY36.14822.890+13.258
5Y146.31921.018+125.301
10Y113.69826.090+87.608
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Sartorius Stedim Biotech SA:

  • The EOD is 37.540. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 44.820. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 4,551.300. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD37.540MRQ44.820-7.280
MRQ44.820TTM4,551.300-4,506.480
TTM4,551.300YOY27.000+4,524.300
TTM4,551.3005Y1,004.319+3,546.982
5Y1,004.31910Y731.835+272.483
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD37.54010.158+27.382
MRQ44.82010.068+34.752
TTM4,551.3001.502+4,549.798
YOY27.0004.281+22.719
5Y1,004.3197.622+996.697
10Y731.8350.247+731.588
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Sartorius is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A PB ratio of 8.72 means the investor is paying €8.72 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Sartorius Stedim Biotech SA:

  • The EOD is 7.302. Based on the equity, the company is overpriced. -1
  • The MRQ is 8.719. Based on the equity, the company is overpriced. -1
  • The TTM is 9.204. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD7.302MRQ8.719-1.416
MRQ8.719TTM9.204-0.486
TTM9.204YOY14.165-4.961
TTM9.2045Y15.439-6.235
5Y15.43910Y13.204+2.235
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD7.3022.434+4.868
MRQ8.7192.782+5.937
TTM9.2042.767+6.437
YOY14.1653.290+10.875
5Y15.4393.530+11.909
10Y13.2044.227+8.977
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Sartorius Stedim Biotech SA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.4570.408+12%2.006-77%0.837-45%0.947-52%
Book Value Per Share--27.47026.613+3%23.097+19%18.501+48%15.577+76%
Current Ratio--1.5101.620-7%1.524-1%1.549-3%1.503+0%
Debt To Asset Ratio--0.6550.585+12%0.519+26%0.484+35%0.450+45%
Debt To Equity Ratio--1.9251.519+27%1.117+72%1.035+86%0.903+113%
Dividend Per Share---0.341-100%0.937-100%0.450-100%0.368-100%
Eps--0.4090.520-21%2.251-82%1.072-62%0.882-54%
Free Cash Flow Per Share--1.3360.436+207%0.467+186%0.760+76%0.569+135%
Free Cash Flow To Equity Per Share--0.1985.803-97%1.034-81%1.968-90%1.377-86%
Gross Profit Margin---1.902-1.260-34%0.480-496%-0.642-66%-0.280-85%
Intrinsic Value_10Y_max--101.530--------
Intrinsic Value_10Y_min--85.573--------
Intrinsic Value_1Y_max--4.547--------
Intrinsic Value_1Y_min--4.463--------
Intrinsic Value_3Y_max--17.951--------
Intrinsic Value_3Y_min--17.050--------
Intrinsic Value_5Y_max--36.524--------
Intrinsic Value_5Y_min--33.532--------
Market Cap19521008662.400-19%23306488408.00023749263031.200-2%31417535626.400-26%26786891572.560-13%20751214078.174+12%
Net Profit Margin--0.0560.111-49%0.251-78%0.172-67%0.167-66%
Operating Margin--0.0650.172-62%0.330-80%0.245-74%0.241-73%
Operating Ratio--0.9350.860+9%0.690+36%0.796+18%0.870+8%
Pb Ratio7.302-19%8.7199.204-5%14.165-38%15.439-44%13.204-34%
Pe Ratio122.619-19%146.398159.645-8%36.148+305%146.319+0%113.698+29%
Price Per Share200.600-19%239.500244.050-2%322.850-26%275.265-13%213.242+12%
Price To Free Cash Flow Ratio37.540-19%44.8204551.300-99%27.000+66%1004.319-96%731.835-94%
Price To Total Gains Ratio438.674-19%523.741474.031+10%113.035+363%822.676-36%608.324-14%
Quick Ratio--0.4800.506-5%0.569-16%0.609-21%0.630-24%
Return On Assets--0.0050.014-63%0.048-89%0.032-84%0.032-84%
Return On Equity--0.0150.031-51%0.103-85%0.063-76%0.059-75%
Total Gains Per Share--0.4570.749-39%2.944-84%1.286-64%1.315-65%
Usd Book Value--2845888720.0002757047850.000+3%2392848190.000+19%1916651172.790+48%1613770495.938+76%
Usd Book Value Change Per Share--0.4870.435+12%2.136-77%0.891-45%1.008-52%
Usd Book Value Per Share--29.24528.332+3%24.589+19%19.696+48%16.583+76%
Usd Dividend Per Share---0.363-100%0.998-100%0.479-100%0.391-100%
Usd Eps--0.4350.553-21%2.396-82%1.141-62%0.939-54%
Usd Free Cash Flow--138398000.00045139040.000+207%48359455.000+186%78738561.220+76%58985154.179+135%
Usd Free Cash Flow Per Share--1.4220.464+207%0.497+186%0.809+76%0.606+135%
Usd Free Cash Flow To Equity Per Share--0.2116.178-97%1.101-81%2.095-90%1.466-86%
Usd Market Cap20782065821.991-19%24812087559.15725283465423.016-2%33447108427.865-26%28517324768.147-13%22091742507.624+12%
Usd Price Per Share213.559-19%254.972259.816-2%343.706-26%293.047-13%227.017+12%
Usd Profit--42371080.00082426655.000-49%233174015.000-82%116745952.280-64%95327734.772-56%
Usd Revenue--752459280.000738699325.000+2%929582105.000-19%665695870.440+13%553064252.083+36%
Usd Total Gains Per Share--0.4870.798-39%3.134-84%1.370-64%1.400-65%
 EOD+4 -4MRQTTM+14 -22YOY+9 -275Y+10 -2610Y+13 -23

3.2. Fundamental Score

Let's check the fundamental score of Sartorius Stedim Biotech SA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15122.619
Price to Book Ratio (EOD)Between0-17.302
Net Profit Margin (MRQ)Greater than00.056
Operating Margin (MRQ)Greater than00.065
Quick Ratio (MRQ)Greater than10.480
Current Ratio (MRQ)Greater than11.510
Debt to Asset Ratio (MRQ)Less than10.655
Debt to Equity Ratio (MRQ)Less than11.925
Return on Equity (MRQ)Greater than0.150.015
Return on Assets (MRQ)Greater than0.050.005
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Sartorius Stedim Biotech SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5021.788
Ma 20Greater thanMa 50254.250
Ma 50Greater thanMa 100255.736
Ma 100Greater thanMa 200241.988
OpenGreater thanClose205.000
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets7,751,600
Total Liabilities5,078,400
Total Stockholder Equity2,637,900
 As reported
Total Liabilities 5,078,400
Total Stockholder Equity+ 2,637,900
Total Assets = 7,751,600

Assets

Total Assets7,751,600
Total Current Assets1,415,100
Long-term Assets6,336,500
Total Current Assets
Cash And Cash Equivalents 116,600
Net Receivables 333,500
Inventory 882,400
Other Current Assets 82,600
Total Current Assets  (as reported)1,415,100
Total Current Assets  (calculated)1,415,100
+/-0
Long-term Assets
Property Plant Equipment 1,633,200
Goodwill 2,851,900
Intangible Assets 1,736,200
Long-term Assets Other 2,700
Long-term Assets  (as reported)6,336,500
Long-term Assets  (calculated)6,224,000
+/- 112,500

Liabilities & Shareholders' Equity

Total Current Liabilities937,300
Long-term Liabilities4,141,100
Total Stockholder Equity2,637,900
Total Current Liabilities
Short-term Debt 79,100
Short Long Term Debt 57,700
Accounts payable 444,500
Other Current Liabilities 224,300
Total Current Liabilities  (as reported)937,300
Total Current Liabilities  (calculated)805,600
+/- 131,700
Long-term Liabilities
Long term Debt 3,509,800
Capital Lease Obligations 114,500
Long-term Liabilities  (as reported)4,141,100
Long-term Liabilities  (calculated)3,624,300
+/- 516,800
Total Stockholder Equity
Common Stock18,400
Retained Earnings 2,390,600
Accumulated Other Comprehensive Income 228,900
Total Stockholder Equity (as reported)2,637,900
Total Stockholder Equity (calculated)2,637,900
+/-0
Other
Capital Stock18,400
Cash and Short Term Investments 116,600
Common Stock Shares Outstanding 92,165
Current Deferred Revenue189,400
Liabilities and Stockholders Equity 7,751,600
Net Debt 3,565,300
Net Invested Capital 6,205,400
Net Working Capital 477,800
Property Plant and Equipment Gross 2,175,700
Short Long Term Debt Total 3,681,900



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-12-31
> Total Assets 
667,857
660,300
687,800
763,300
814,900
908,100
1,016,300
1,143,800
1,195,849
1,304,800
1,341,700
1,364,800
1,403,905
1,457,200
1,505,000
1,585,100
1,571,461
1,660,400
1,693,800
1,771,800
1,820,421
1,895,400
2,224,100
2,361,500
3,069,336
3,313,000
3,521,900
3,976,100
3,951,098
4,158,700
4,375,100
5,097,100
5,065,400
5,096,700
5,187,200
7,958,900
7,751,600
7,751,6007,958,9005,187,2005,096,7005,065,4005,097,1004,375,1004,158,7003,951,0983,976,1003,521,9003,313,0003,069,3362,361,5002,224,1001,895,4001,820,4211,771,8001,693,8001,660,4001,571,4611,585,1001,505,0001,457,2001,403,9051,364,8001,341,7001,304,8001,195,8491,143,8001,016,300908,100814,900763,300687,800660,300667,857
   > Total Current Assets 
185,568
176,600
211,100
237,300
249,100
287,000
341,900
426,900
431,733
521,200
469,800
475,600
490,845
535,800
531,300
595,500
552,529
587,200
609,100
652,700
633,802
704,300
816,800
961,200
875,216
1,061,800
1,252,000
1,387,800
1,455,629
1,563,300
1,697,100
1,780,900
1,671,200
1,646,200
1,618,000
1,525,000
1,415,100
1,415,1001,525,0001,618,0001,646,2001,671,2001,780,9001,697,1001,563,3001,455,6291,387,8001,252,0001,061,800875,216961,200816,800704,300633,802652,700609,100587,200552,529595,500531,300535,800490,845475,600469,800521,200431,733426,900341,900287,000249,100237,300211,100176,600185,568
       Cash And Cash Equivalents 
54,849
26,500
40,300
40,800
27,500
43,000
29,400
38,600
34,756
99,600
33,000
30,300
32,552
42,700
25,800
56,700
23,975
25,800
25,500
35,000
27,643
69,900
89,300
165,900
59,762
149,400
254,700
226,800
223,626
165,100
156,100
145,500
107,100
94,000
110,000
99,300
116,600
116,60099,300110,00094,000107,100145,500156,100165,100223,626226,800254,700149,40059,762165,90089,30069,90027,64335,00025,50025,80023,97556,70025,80042,70032,55230,30033,00099,60034,75638,60029,40043,00027,50040,80040,30026,50054,849
       Short-term Investments 
0
0
0
0
0
7,500
6,400
10,000
8,265
17,400
17,200
29,300
11,300
27,500
16,900
20,100
19,212
15,700
9,900
10,900
18,297
48,700
0
65,500
9,843
15,200
0
9,700
13,721
47,100
24,900
16,200
25,900
19,000
14,300
19,400
0
019,40014,30019,00025,90016,20024,90047,10013,7219,700015,2009,84365,500048,70018,29710,9009,90015,70019,21220,10016,90027,50011,30029,30017,20017,4008,26510,0006,4007,50000000
       Net Receivables 
0
0
0
0
0
0
0
0
204,853
209,200
217,900
210,300
237,623
241,200
247,800
255,400
235,769
248,700
247,400
266,100
242,188
215,300
232,100
253,300
263,962
310,500
320,300
368,300
371,716
409,000
440,000
447,000
405,000
387,900
358,800
333,900
333,500
333,500333,900358,800387,900405,000447,000440,000409,000371,716368,300320,300310,500263,962253,300232,100215,300242,188266,100247,400248,700235,769255,400247,800241,200237,623210,300217,900209,200204,85300000000
       Inventory 
46,718
56,600
62,500
78,000
89,700
105,900
137,700
170,300
171,057
180,800
179,800
184,000
185,604
203,000
215,700
240,000
252,002
269,900
285,900
314,400
328,164
340,500
407,900
437,500
472,305
534,800
599,600
703,900
782,954
857,500
964,100
1,058,600
1,024,800
1,060,900
1,033,100
992,000
882,400
882,400992,0001,033,1001,060,9001,024,8001,058,600964,100857,500782,954703,900599,600534,800472,305437,500407,900340,500328,164314,400285,900269,900252,002240,000215,700203,000185,604184,000179,800180,800171,057170,300137,700105,90089,70078,00062,50056,60046,718
   > Long-term Assets 
482,289
483,700
476,700
526,000
565,800
621,100
674,400
716,900
0
0
871,800
0
0
0
973,600
0
1,018,932
0
1,084,600
1,119,100
1,186,619
1,191,100
1,407,300
1,400,300
2,194,120
2,251,200
2,269,900
2,588,300
2,495,469
2,595,400
2,678,100
3,316,300
3,394,200
3,450,400
3,569,200
6,433,900
6,336,500
6,336,5006,433,9003,569,2003,450,4003,394,2003,316,3002,678,1002,595,4002,495,4692,588,3002,269,9002,251,2002,194,1201,400,3001,407,3001,191,1001,186,6191,119,1001,084,60001,018,9320973,600000871,80000716,900674,400621,100565,800526,000476,700483,700482,289
       Property Plant Equipment 
111,765
113,100
111,700
159,600
163,200
179,500
203,900
235,700
261,464
280,100
292,700
311,000
228,115
342,900
382,700
401,300
255,261
485,900
498,700
524,600
466,754
549,600
561,700
566,400
643,950
693,800
726,000
799,800
928,414
986,600
1,066,700
1,193,400
1,292,200
1,355,300
1,455,200
1,564,200
1,633,200
1,633,2001,564,2001,455,2001,355,3001,292,2001,193,4001,066,700986,600928,414799,800726,000693,800643,950566,400561,700549,600466,754524,600498,700485,900255,261401,300382,700342,900228,115311,000292,700280,100261,464235,700203,900179,500163,200159,600111,700113,100111,765
       Goodwill 
250,277
250,300
250,300
254,800
279,200
307,100
336,500
332,300
344,777
344,900
388,900
388,100
386,045
384,100
383,900
384,500
384,695
385,800
383,300
383,700
426,890
423,100
463,100
459,000
875,162
880,100
866,800
934,700
820,702
832,400
836,100
1,125,200
1,136,400
1,135,300
1,150,000
2,319,900
2,851,900
2,851,9002,319,9001,150,0001,135,3001,136,4001,125,200836,100832,400820,702934,700866,800880,100875,162459,000463,100423,100426,890383,700383,300385,800384,695384,500383,900384,100386,045388,100388,900344,900344,777332,300336,500307,100279,200254,800250,300250,300250,277
       Long Term Investments 
0
0
0
0
0
0
0
0
2,272
3,100
9,400
11,500
11,808
11,900
6,100
4,700
5,644
5,900
5,900
6,100
15,079
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000015,0796,1005,9005,9005,6444,7006,10011,90011,80811,5009,4003,1002,27200000000
       Intangible Assets 
106,590
104,900
99,100
95,900
113,400
122,400
121,000
135,700
111,484
143,100
169,400
167,300
124,932
170,800
189,600
188,300
177,493
178,900
179,500
185,800
180,091
182,000
347,400
338,800
633,521
632,300
631,600
805,500
684,416
705,300
699,100
917,300
876,900
870,600
879,400
2,453,900
1,736,200
1,736,2002,453,900879,400870,600876,900917,300699,100705,300684,416805,500631,600632,300633,521338,800347,400182,000180,091185,800179,500178,900177,493188,300189,600170,800124,932167,300169,400143,100111,484135,700121,000122,400113,40095,90099,100104,900106,590
       Long-term Assets Other 
3,644
3,300
4,400
3,100
1,600
2,100
2,400
2,400
0
0
10,200
0
0
0
6,900
0
6,274
0
6,400
7,000
7,929
700
8,000
14,800
10,352
15,700
15,500
10,200
14,375
47,700
25,500
16,900
28,100
21,400
17,100
21,800
2,700
2,70021,80017,10021,40028,10016,90025,50047,70014,37510,20015,50015,70010,35214,8008,0007007,9297,0006,40006,27406,90000010,200002,4002,4002,1001,6003,1004,4003,3003,644
> Total Liabilities 
274,658
300,500
316,800
356,100
362,400
415,600
426,500
466,600
432,293
497,400
538,200
527,000
524,451
541,800
580,100
609,400
526,587
604,700
586,600
595,200
642,792
649,500
936,200
983,900
1,586,419
1,756,800
1,828,800
2,212,700
2,217,871
2,159,100
2,247,700
2,747,700
2,551,200
2,642,300
2,584,500
5,330,200
5,078,400
5,078,4005,330,2002,584,5002,642,3002,551,2002,747,7002,247,7002,159,1002,217,8712,212,7001,828,8001,756,8001,586,419983,900936,200649,500642,792595,200586,600604,700526,587609,400580,100541,800524,451527,000538,200497,400432,293466,600426,500415,600362,400356,100316,800300,500274,658
   > Total Current Liabilities 
119,692
135,700
151,700
163,100
237,800
171,100
284,400
316,700
284,365
350,500
385,200
336,000
350,444
366,400
411,400
440,600
381,975
436,900
416,200
424,800
427,345
433,700
492,900
536,700
567,693
708,000
792,400
938,600
1,037,119
1,025,400
1,158,200
1,192,300
1,035,900
1,151,500
922,000
853,600
937,300
937,300853,600922,0001,151,5001,035,9001,192,3001,158,2001,025,4001,037,119938,600792,400708,000567,693536,700492,900433,700427,345424,800416,200436,900381,975440,600411,400366,400350,444336,000385,200350,500284,365316,700284,400171,100237,800163,100151,700135,700119,692
       Short-term Debt 
0
0
0
0
0
7,500
6,400
10,000
102,322
174,400
17,200
114,600
95,933
98,300
16,900
134,000
19,212
49,100
9,900
10,900
18,297
0
0
29,100
23,839
40,300
39,400
63,800
40,444
43,800
146,200
73,700
23,900
194,600
27,000
34,100
79,100
79,10034,10027,000194,60023,90073,700146,20043,80040,44463,80039,40040,30023,83929,1000018,29710,9009,90049,10019,212134,00016,90098,30095,933114,60017,200174,400102,32210,0006,4007,50000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
102,322
174,400
199,800
114,600
95,933
98,300
121,200
134,000
89,817
49,100
79,700
49,000
43,545
25,900
22,500
18,800
13,112
27,600
26,400
50,600
25,505
27,700
130,700
57,400
4,400
174,900
7,000
11,900
57,700
57,70011,9007,000174,9004,40057,400130,70027,70025,50550,60026,40027,60013,11218,80022,50025,90043,54549,00079,70049,10089,817134,000121,20098,30095,933114,600199,800174,400102,32200000000
       Accounts payable 
0
0
0
0
0
0
0
0
67,987
101,900
110,700
104,500
77,210
126,500
154,000
155,600
103,568
167,100
173,200
195,700
115,999
199,100
222,100
239,000
174,733
364,600
407,400
439,800
251,361
506,000
520,800
520,300
251,700
454,900
440,400
412,100
444,500
444,500412,100440,400454,900251,700520,300520,800506,000251,361439,800407,400364,600174,733239,000222,100199,100115,999195,700173,200167,100103,568155,600154,000126,50077,210104,500110,700101,90067,98700000000
       Other Current Liabilities 
0
0
0
0
0
0
0
0
111,490
99,000
68,300
79,100
143,748
108,500
98,500
101,800
147,538
171,700
41,100
121,700
216,080
161,100
183,300
268,600
369,121
303,100
345,600
279,600
580,288
475,600
491,200
598,300
760,300
502,000
94,100
93,500
224,300
224,30093,50094,100502,000760,300598,300491,200475,600580,288279,600345,600303,100369,121268,600183,300161,100216,080121,70041,100171,700147,538101,80098,500108,500143,74879,10068,30099,000111,49000000000
   > Long-term Liabilities 
154,966
164,800
165,100
193,000
124,600
244,500
142,100
149,900
0
0
153,000
0
0
0
168,700
0
144,612
0
170,400
170,400
215,447
215,800
443,300
447,200
1,018,726
1,048,800
1,036,400
1,274,100
1,180,752
1,133,700
1,089,500
1,555,400
1,515,300
1,490,800
1,662,500
4,476,600
4,141,100
4,141,1004,476,6001,662,5001,490,8001,515,3001,555,4001,089,5001,133,7001,180,7521,274,1001,036,4001,048,8001,018,726447,200443,300215,800215,447170,400170,4000144,6120168,700000153,00000149,900142,100244,500124,600193,000165,100164,800154,966
       Other Liabilities 
0
0
0
0
0
0
0
0
121,875
122,100
129,000
127,500
111,928
114,200
108,800
109,900
86,511
87,500
89,200
88,300
134,749
135,000
144,200
145,700
455,781
479,900
465,900
694,800
595,680
546,600
503,500
463,600
403,600
378,700
0
716,700
0
0716,7000378,700403,600463,600503,500546,600595,680694,800465,900479,900455,781145,700144,200135,000134,74988,30089,20087,50086,511109,900108,800114,200111,928127,500129,000122,100121,87500000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
32,498
0
0
0
47,938
0
0
0
66,412
0
0
0
83,785
0
0
0
101,042
0
0
0
120,922
0
0
0
164,200
0
0
0
0
0000164,200000120,922000101,04200083,78500066,41200047,93800032,49800000000
> Total Stockholder Equity
0
0
0
0
0
0
0
0
758,005
801,300
796,800
831,100
872,028
907,700
917,300
967,600
1,036,398
1,046,800
1,099,200
1,167,800
1,158,789
1,226,800
1,258,900
1,377,600
1,460,041
1,530,900
1,668,500
1,668,300
1,655,866
1,923,100
2,051,500
2,272,800
2,449,300
2,420,300
2,569,200
2,594,600
2,637,900
2,637,9002,594,6002,569,2002,420,3002,449,3002,272,8002,051,5001,923,1001,655,8661,668,3001,668,5001,530,9001,460,0411,377,6001,258,9001,226,8001,158,7891,167,8001,099,2001,046,8001,036,398967,600917,300907,700872,028831,100796,800801,300758,00500000000
   Common Stock
0
0
0
0
0
0
0
0
18,083
18,200
18,100
18,400
18,436
18,400
18,400
18,400
18,436
18,400
18,400
18,400
18,436
18,400
18,400
18,400
18,436
18,400
18,400
18,400
18,436
18,400
18,400
18,400
18,400
18,400
18,400
18,400
18,400
18,40018,40018,40018,40018,40018,40018,40018,40018,43618,40018,40018,40018,43618,40018,40018,40018,43618,40018,40018,40018,43618,40018,40018,40018,43618,40018,10018,20018,08300000000
   Retained Earnings 
44,036
58,700
82,300
116,100
160,200
198,600
331,500
421,200
490,275
551,600
547,200
581,200
612,699
657,800
667,400
717,600
786,436
796,900
849,200
917,900
908,827
976,900
1,008,900
1,097,300
1,210,079
1,280,900
1,418,500
1,418,400
1,405,904
1,673,100
1,801,600
2,022,800
2,179,000
2,170,300
2,304,100
2,344,700
2,390,600
2,390,6002,344,7002,304,1002,170,3002,179,0002,022,8001,801,6001,673,1001,405,9041,418,4001,418,5001,280,9001,210,0791,097,3001,008,900976,900908,827917,900849,200796,900786,436717,600667,400657,800612,699581,200547,200551,600490,275421,200331,500198,600160,200116,10082,30058,70044,036
   Capital Surplus 0000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
249,647
231,500
247,800
231,500
240,893
231,500
237,500
231,600
239,514
231,500
234,000
231,500
240,895
231,500
231,200
261,900
231,526
231,600
231,600
231,500
231,526
231,600
231,500
231,600
251,900
100
15,100
231,500
0
0231,50015,100100251,900231,600231,500231,600231,526231,500231,600231,600231,526261,900231,200231,500240,895231,500234,000231,500239,514231,600237,500231,500240,893231,500247,800231,500249,64700000000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue2,775,500
Cost of Revenue-1,542,000
Gross Profit1,233,5001,233,500
 
Operating Income (+$)
Gross Profit1,233,500
Operating Expense-749,000
Operating Income484,500484,500
 
Operating Expense (+$)
Research Development129,500
Selling General Administrative167,100
Selling And Marketing Expenses449,100
Operating Expense749,000745,700
 
Net Interest Income (+$)
Interest Income6,200
Interest Expense-138,500
Other Finance Cost-9,700
Net Interest Income-122,600
 
Pretax Income (+$)
Operating Income484,500
Net Interest Income-122,600
Other Non-Operating Income Expenses0
Income Before Tax (EBT)401,100567,900
EBIT - interestExpense = 346,000
398,700
448,200
Interest Expense138,500
Earnings Before Interest and Taxes (EBIT)484,500539,600
Earnings Before Interest and Taxes (EBITDA)722,100
 
After tax Income (+$)
Income Before Tax401,100
Tax Provision-89,000
Net Income From Continuing Ops312,100312,100
Net Income309,700
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,291,000
Total Other Income/Expenses Net-83,400122,600
 

Technical Analysis of Sartorius
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sartorius. The general trend of Sartorius is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sartorius's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Sartorius Stedim Biotech SA.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 220.71 < 240.26 < 248.30.

The bearish price targets are: 196.27 > 181.36 > 165.56.

Tweet this
Sartorius Stedim Biotech SA Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Sartorius Stedim Biotech SA. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Sartorius Stedim Biotech SA Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Sartorius Stedim Biotech SA. The current macd is -9.28201138.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Sartorius price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Sartorius. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Sartorius price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Sartorius Stedim Biotech SA Daily Moving Average Convergence/Divergence (MACD) ChartSartorius Stedim Biotech SA Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Sartorius Stedim Biotech SA. The current adx is 24.55.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Sartorius shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Sartorius Stedim Biotech SA Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Sartorius Stedim Biotech SA. The current sar is 252.30.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Sartorius Stedim Biotech SA Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Sartorius Stedim Biotech SA. The current rsi is 21.79. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Sartorius Stedim Biotech SA Daily Relative Strength Index (RSI) ChartSartorius Stedim Biotech SA Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Sartorius Stedim Biotech SA. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Sartorius price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Sartorius Stedim Biotech SA Daily Stochastic Oscillator ChartSartorius Stedim Biotech SA Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Sartorius Stedim Biotech SA. The current cci is -321.29005311.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Sartorius Stedim Biotech SA Daily Commodity Channel Index (CCI) ChartSartorius Stedim Biotech SA Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Sartorius Stedim Biotech SA. The current cmo is -69.90591138.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Sartorius Stedim Biotech SA Daily Chande Momentum Oscillator (CMO) ChartSartorius Stedim Biotech SA Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Sartorius Stedim Biotech SA. The current willr is -92.30769231.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Sartorius Stedim Biotech SA Daily Williams %R ChartSartorius Stedim Biotech SA Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Sartorius Stedim Biotech SA.

Sartorius Stedim Biotech SA Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Sartorius Stedim Biotech SA. The current atr is 11.09.

Sartorius Stedim Biotech SA Daily Average True Range (ATR) ChartSartorius Stedim Biotech SA Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Sartorius Stedim Biotech SA. The current obv is -407,381.

Sartorius Stedim Biotech SA Daily On-Balance Volume (OBV) ChartSartorius Stedim Biotech SA Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Sartorius Stedim Biotech SA. The current mfi is 18.39.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Sartorius Stedim Biotech SA Daily Money Flow Index (MFI) ChartSartorius Stedim Biotech SA Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Sartorius Stedim Biotech SA.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Sartorius Stedim Biotech SA Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Sartorius Stedim Biotech SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5021.788
Ma 20Greater thanMa 50254.250
Ma 50Greater thanMa 100255.736
Ma 100Greater thanMa 200241.988
OpenGreater thanClose205.000
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Sartorius with someone you think should read this too:
  • Are you bullish or bearish on Sartorius? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Sartorius? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Sartorius Stedim Biotech SA

I send you an email if I find something interesting about Sartorius Stedim Biotech SA.


Comments

How you think about this?

Leave a comment

Stay informed about Sartorius Stedim Biotech SA.

Receive notifications about Sartorius Stedim Biotech SA in your mailbox!